Volume 2, Issue 6 pp. 372-376

A Review of the Selective Serotonin Reuptake Inhibitors in Bulimia Nervosa

Kelly P. Kirby PharmD

Kelly P. Kirby PharmD

Massachusetts College of Pharmacy and Health Sciences

Search for more papers by this author
Brenda Dietz PharmD

Brenda Dietz PharmD

Children's Hospital, Boston, Massachusetts

Search for more papers by this author
Alana D. Arnold PharmD

Alana D. Arnold PharmD

Children's Hospital, Boston, Massachusetts

Search for more papers by this author
First published: 04 January 2002
Citations: 1
Reprint requests to Kelly P. Kirby, PharmD, Massachusetts College of Pharmacy and Health Sciences, 179 Longwood Avenue, Boston, MA 02115.

Abstract

Successful treatment of eating disorders often includes drug therapy along with psychotherapy and nutritional counseling. Selective serotonin reuptake inhibitors are attractive agents for use in eating disorders due to their favorable side effect profiles. Currently, fluoxetine is the only FDA approved agent for treatment of bulimia nervosa; however, fluvoxamine has also been studied for use in this disorder. This review examines the evidence for the use of selective serotonin reuptake inhibitors in bulimia, and summarizes the pharmacokinetics, side effects, and drug interactions of selective serotonin reuptake inhibitors available in the United States.

The full text of this article hosted at iucr.org is unavailable due to technical difficulties.